Recently, IL-17+ γδ T cells have been shown to promote resistance to CDK4/6 inhibitors in hormone receptor (HR)+ breast cancer, at least in part by favoring the repolarization of tumor-associated macrophages (TAMs) toward an immunosuppressive CX3CR1+ phenotype (Buque et al, 2020; Petroni et al, 2025). Here, IL17A is linked to breast carcinoma.